The global Orally Administered Vaccine market size is predicted to grow from US$ 2908 million in 2025 to US$ 4098 million in 2031; it is expected to grow at a CAGR of 5.9% from 2025 to 2031.

Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.

The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.

Infinity Market Research newest research report, the Orally Administered Vaccine Industry Forecast looks at past sales and reviews total world Orally Administered Vaccine sales in 2024, providing a comprehensive analysis by region and market sector of projected Orally Administered Vaccine sales for 2025 through 2031. With Orally Administered Vaccine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Orally Administered Vaccine industry.

This Insight Report provides a comprehensive analysis of the global Orally Administered Vaccine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Orally Administered Vaccine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Orally Administered Vaccine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Orally Administered Vaccine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Orally Administered Vaccine.

This report presents a comprehensive overview, market shares, and growth opportunities of Orally Administered Vaccine market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Rotavirus Vaccine
    Cholera Vaccine
    Oral Polio Vaccine
    Other

Segmentation by Application:

    Public
    Private

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Merck
    GSK
    Sanofi
    Lanzhou Institute
    Serum Institute
    Valneva
    Shanghai United Cell
    Bibcol
    PaxVax
    Vabiotech
    Tiantan Biological
    EuBiologics
    Panacea Biotec Ltd
    Bio-Med
    Halfkin Bio-Pharmaceuticals

Key Questions Addressed in this Report

What is the 10-year outlook for the global Orally Administered Vaccine market?
What factors are driving Orally Administered Vaccine market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Orally Administered Vaccine market opportunities vary by end market size?
How does Orally Administered Vaccine break out by Type, by Application?